Paper Review Records
全部论文审稿周期
10 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
55
天
Development of potent and selective ENPP1 inhibitors based on imidazo[1,2-a]pyrazine and pyrazine scaffolds for cancer immunotherapy
作者
Zhiyue He; Yingying Zhang; Shiping Zhan; Tian Cao; Wanru Bai; Bozhi Zhou; Jie Yu; Huiying Zeng; Jingyi Zhou; Fuyun Tian; Xiaoyan Chen; Sulin Zhang; Mingyue Zheng; Xiaowei Wu展开收起
作者单位
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China; School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China; School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, China; The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China; University of Chinese Academy of Sciences, Beijing, 100049, China; College of Pharmacy, Guangdong Pharmaceutical University, Guangdong, 510006, China; School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China; School of Pharmaceutical Science and Technology, Hangzhou Institute of Advanced Study, UCAS, Hangzhou, 310024, China展开收起
43
天
Discovery and characterization of a sophoridine-derived TNIK inhibitor with antitumor activity in hepatocellular carcinoma
作者
Yongquan Wei; Ziyi Wang; Die Sun; Zexu Xing; Haixia Yu; Lisheng Wang展开收起
作者单位
School of Chemistry and Chemical Engineering, Guangxi University, Nanning, 530004, China; School of Chemical Engineering, Jilin Vocational College of Industry and Technology, Jilin, 132000, China; Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, 530004, China展开收起
155
天
Synthesis and biological evaluation of novel gemcitabine-dexamethasone hybrid as potent antitumor agents against esophageal cancer
作者
Ruoxin Liu; Na Liu; Yimeng Wang; Jingyu Yang; Yuxin Chen; Xingjia Ma; Weijin Sheng; Kai Lv; Xiujun Liu展开收起
作者单位
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China展开收起
45
天
Discovery of a novel anti-ischemic acute kidney injury candidate from pestaphilones, a new subtype of azaphilones derived from marine fungus
作者
Jianglian She; Jian Cai; Chuanliang Wei; Xiaoqiang He; Rongxiang Qiu; Xin Qi; Xinlong Li; Tanwei Gu; Xi Zhang; Zhihao Zeng; Xinqi Chen; Yuanxin Tian; Wei Xu; Yonghong Liu; Xuefeng Zhou; Lan Tang展开收起
作者单位
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China; State Key Laboratory of Tropical Oceanography, Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, 510301, China; University of Chinese Academy of Sciences, Beijing, 100049, China; Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China; Guangxi Key Laboratory of Marine Drugs, Institute of Marine Drugs, Guangxi University of Chinese Medicine, Nanning, 530200, China展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天